Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread ...
Table 3 presents a summary of the findings of the ATTEST–AMPLE network randomized trial of infliximab or adalimumab versus abatacept for RA. Compared with infliximab (iv.), abatacept (iv./ ...
#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback